HC Wainwright & Co. Reiterates Buy on Viridian Therapeutics, Maintains $27 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Viridian Therapeutics (NASDAQ:VRDN) and maintained a price target of $27.
July 16, 2024 | 12:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Viridian Therapeutics and maintained a price target of $27.
The reiteration of a Buy rating and maintenance of a $27 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100